Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis

A technique for eluting stents and restenosis, applied in the fields of stents, medical science, surgery, etc., can solve problems such as stents that cannot be effectively solved at the same time, and achieve the effects of reducing stent thrombosis, promoting endothelial repair, and reducing restenosis.

Inactive Publication Date: 2008-07-09
杨巍 +1
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] The purpose of the present invention is to solve the problem that the existing drug-eluting stent cannot effectively solve the problem of restenosis in the stent...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis
  • Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0020] Embodiment 1: (See Figures 1-3) In this embodiment, the drug-eluting stent that promotes endothelial repair and prevents restenosis is composed of a stent matrix, an intermediate layer, and an antibody coating from the inside to the outside. The base of the bracket is mesh; the material of the base of the bracket is stainless steel, polymer, nickel-titanium alloy, magnesium alloy, tantalum or gold. The middle layer includes at least one drug layer composed of one or more of diarsenic trioxide, tetraarsenic hexaoxide and organic arsenic, wherein the organic arsenic is p-aminophenylarsine acid, sodium p-aminophenylarsine or 3-nitro- 4-Hydroxyphenylarsineic acid. When the drug layer is a mixture, the arsenic trioxide, tetraarsenic hexaoxide and organic arsenic are mixed in any ratio. The antibody in the antibody coating is a monoclonal antibody, a polyclonal antibody, an animal antibody or a human antibody capable of recognizing and adsorbing endothelial progenitor cells,...

specific Embodiment approach 2

[0024] Specific embodiment two: (see Fig. 2, Fig. 3) the difference between this embodiment and specific embodiment one is: the intermediate layer also comprises at least one layer of controlled release layer, and the material of controlled release layer is macromolecule material, and macromolecule material is polymer. Wherein said polymer is polyester, chitosan, cellulose, extracellular matrix, polylactic acid polyglycolic acid copolymer, styrene-isobutylene-styrene copolymer, hydroxystyrene-isobutylene-hydroxystyrene Copolymers and their derivatives, polyvinyl alcohol grafted polylactic acid polyglycolic acid copolymer, phosphorylcholine and L-polylactic acid, polyglycolic acid polylactic acid copolymer, ethylene-vinyl acetate copolymer (EVAC), polymethacrylic acid n-Butyl ester (PBMA), methyl methacrylate (MMA), polycaprolactone or polyurethane.

[0025]In this embodiment, the controlled release layer is located between the stent matrix and the drug layer, or between the d...

specific Embodiment approach 3

[0027] Embodiment 3: The difference between this embodiment and Embodiment 1 is that the middle layer of the drug-eluting stent that promotes endothelial repair and prevents restenosis is made of one or more of arsenic trioxide, tetraarsenic hexoxide, and organic arsenic. A composition of arsenic-containing drugs and polymers. When the arsenic-containing medicine is a mixture, the diarsenic trioxide, tetraarsenic hexaoxide and organic arsenic are mixed in any ratio; the total weight of the arsenic-containing medicine is 5-200 micrograms. Wherein the organic arsenic is p-aminophenylarsine, sodium p-aminophenylarsine or 3-nitro-4-hydroxyphenylarsine.

[0028] In this embodiment, the ratio of the polymer material and the drug component can be added as needed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

A drug eluting stent for promoting endothelium repairing and preventing restenosis relates to a reticular drug eluting stent. The invention solves the problem that the current drug eluting stents cannot effectively prevent the restenosis and thrombus in the stent at the same time. The drug eluting stent of the invention consists of a stent matrix, a middle layer and an antibody coating from inside to outside; the middle layer at least consists of a drug layer consisting of one or several of arsenous oxide, tetra-arsenic hexoxide and organic arsenic; the antibody coating is an antibody capable of capturing endothelia1 progenitor cells. The middle layer also includes at least a control release layer made of polymer material; release of the drug layer is controlled by the polymer material. The product of the invention can prohibit the proliferation of smooth muscle cells, and reduce the possibility of restenosis in the stent; capture the endothelia1 progenitor cells in the blood, and re-gather the endothelia1 progenitor cells where damage is produced after the equipment is implanted, so as to promote the healing of the endothelium and the recovery of the functions, and reduce thrombus in the stent.

Description

technical field [0001] The invention relates to a mesh drug-eluting stent, which is used for implanting blood vessels or tubular structures in the body. Background technique [0002] Atherosclerosis is a leading cause of death and disability in the world. Atherosclerosis leads to stenosis and even occlusion of the lumen, leading to ischemia and necrosis of the blood-supplying tissue, causing disability or life-threatening. Coronary atherosclerotic disease (CAD) is the most common and serious life-threatening disease in modern society. In the United States, 1.15 million people die of myocardial infarction every year, of which 600,000 (40%) die of acute myocardial infarction. The incidence of myocardial infarction in China is increasing year by year, seriously endangering people's health and increasing the social medical burden. [0003] Coronary heart disease can be treated by percutaneous transluminal coronary angioplasty (PTCA). In the United States, more than 1 million ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/16A61L31/12A61F2/82A61F2/90
Inventor 葛均波杨巍程树军沈雳钟伟田野
Owner 杨巍
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap